Moderna rises as index inclusion and oncology optimism stay in focus

Moderna (MRNA) is up 4.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely drivers appear to be fresh buying tied to Moderna’s upcoming addition to the Nasdaq-100 and continued investor optimism around its cancer pipeline. Shares have also stayed supported by the company’s recent Phase 3 melanoma win, which reinforced expectations that oncology could become a major commercial growth pillar.

Details:

Moderna is scheduled to join the Nasdaq-100 before the market opens on October 9, 2026, a change that can create index-fund demand and raise visibility among large investors.

In September, Moderna and its partner Merck said their Phase 3 INTerpath-001 study met its main goals in resected stage IIB-IV melanoma, a closely watched milestone for the personalized cancer vaccine program.

The company recently added a chief operating officer role and said the move supports increasing scale and diversification as it prepares for a potential launch of intismeran autogene and expands in oncology.

With full melanoma data expected later this month, traders may be positioning ahead of another important catalyst; this could be because the market is looking for more evidence on durability and broader commercial potential.

Sources:

Moderna press release, SEC, Nasdaq

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MRNA Insider Trading Activity

$MRNA insiders have traded $MRNA stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.

Here’s a breakdown of recent trading of $MRNA stock by insiders over the last 6 months:

STEPHANE BANCEL (Chief Executive Officer) has made 0 purchases and 4 sales selling 499,246 shares for an estimated $28,715,011.
STEPHEN HOGE (President) has made 0 purchases and 5 sales selling 240,583 shares for an estimated $20,618,266.
JAMES M MOCK (Chief Financial Officer) has made 0 purchases and 2 sales selling 34,836 shares for an estimated $4,685,093.
SHANNON THYME KLINGER (Chief Legal Officer) has made 0 purchases and 2 sales selling 6,942 shares for an estimated $659,316.
NOUBAR AFEYAN sold 9,263 shares for an estimated $433,878
ABBAS HUSSAIN sold 5,682 shares for an estimated $264,951

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive MRNA Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$MRNA Hedge Fund Activity

We have seen 367 institutional investors add shares of $MRNA stock to their portfolio, and 318 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 6,187,867 shares (+13.5%) to their portfolio in Q2 2026, for an estimated $433,336,326
D. E. SHAW & CO., INC. removed 5,157,808 shares (-99.5%) from their portfolio in Q2 2026, for an estimated $361,201,294
PRICE T ROWE ASSOCIATES INC /MD/ added 4,850,982 shares (+656.8%) to their portfolio in Q2 2026, for an estimated $339,714,269
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 4,838,884 shares (+inf%) to their portfolio in Q2 2026, for an estimated $338,867,046
CAPITAL WORLD INVESTORS added 3,579,302 shares (+19.1%) to their portfolio in Q2 2026, for an estimated $250,658,519
ALYESKA INVESTMENT GROUP, L.P. removed 3,490,366 shares (-86.2%) from their portfolio in Q2 2026, for an estimated $244,430,330
BAILLIE GIFFORD & CO removed 2,373,736 shares (-11.5%) from their portfolio in Q2 2026, for an estimated $166,232,732

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$MRNA Congressional Stock Trading

Members of Congress have traded $MRNA stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $MRNA stock by members of Congress over the last 6 months:

REPRESENTATIVE MARIA ELVIRA SALAZAR has traded it 2 times. They made 1 purchase worth up to $15,000 on 08/19 and 1 sale worth up to $15,000 on 08/19.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$MRNA Price Targets

Multiple analysts have issued price targets for $MRNA recently. We have seen 7 analysts offer price targets for $MRNA in the last 6 months, with a median target of $45.0.

Here are some recent targets:

Matthew Harrison from Morgan Stanley set a target price of $39.0 on 07/08/2026
Luca Issi from RBC Capital set a target price of $45.0 on 07/07/2026
Dimple Gosai from B of A Securities set a target price of $38.0 on 07/07/2026
Edward Tenthoff from Piper Sandler set a target price of $77.0 on 06/26/2026
Salveen Richter from Goldman Sachs set a target price of $49.0 on 05/04/2026
Cory Kasimov from Evercore ISI Group set a target price of $50.0 on 05/04/2026
Eliana Merle from UBS set a target price of $45.0 on 05/04/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.